QQQ   303.59 (-0.85%)
AAPL   151.73 (-1.79%)
MSFT   256.77 (-0.61%)
META   186.06 (-0.25%)
GOOGL   102.90 (-1.79%)
AMZN   102.18 (-1.17%)
TSLA   194.76 (+2.52%)
NVDA   210.89 (-0.05%)
NIO   10.93 (-2.32%)
BABA   105.45 (-0.83%)
AMD   83.68 (-2.80%)
T   19.58 (-1.26%)
F   13.14 (-0.68%)
MU   59.98 (-3.89%)
CGC   2.95 (+1.03%)
GE   82.35 (+0.48%)
DIS   109.87 (-0.76%)
AMC   6.80 (+11.84%)
PFE   43.76 (-0.68%)
PYPL   82.33 (-3.73%)
NFLX   361.48 (-1.21%)
QQQ   303.59 (-0.85%)
AAPL   151.73 (-1.79%)
MSFT   256.77 (-0.61%)
META   186.06 (-0.25%)
GOOGL   102.90 (-1.79%)
AMZN   102.18 (-1.17%)
TSLA   194.76 (+2.52%)
NVDA   210.89 (-0.05%)
NIO   10.93 (-2.32%)
BABA   105.45 (-0.83%)
AMD   83.68 (-2.80%)
T   19.58 (-1.26%)
F   13.14 (-0.68%)
MU   59.98 (-3.89%)
CGC   2.95 (+1.03%)
GE   82.35 (+0.48%)
DIS   109.87 (-0.76%)
AMC   6.80 (+11.84%)
PFE   43.76 (-0.68%)
PYPL   82.33 (-3.73%)
NFLX   361.48 (-1.21%)
QQQ   303.59 (-0.85%)
AAPL   151.73 (-1.79%)
MSFT   256.77 (-0.61%)
META   186.06 (-0.25%)
GOOGL   102.90 (-1.79%)
AMZN   102.18 (-1.17%)
TSLA   194.76 (+2.52%)
NVDA   210.89 (-0.05%)
NIO   10.93 (-2.32%)
BABA   105.45 (-0.83%)
AMD   83.68 (-2.80%)
T   19.58 (-1.26%)
F   13.14 (-0.68%)
MU   59.98 (-3.89%)
CGC   2.95 (+1.03%)
GE   82.35 (+0.48%)
DIS   109.87 (-0.76%)
AMC   6.80 (+11.84%)
PFE   43.76 (-0.68%)
PYPL   82.33 (-3.73%)
NFLX   361.48 (-1.21%)
QQQ   303.59 (-0.85%)
AAPL   151.73 (-1.79%)
MSFT   256.77 (-0.61%)
META   186.06 (-0.25%)
GOOGL   102.90 (-1.79%)
AMZN   102.18 (-1.17%)
TSLA   194.76 (+2.52%)
NVDA   210.89 (-0.05%)
NIO   10.93 (-2.32%)
BABA   105.45 (-0.83%)
AMD   83.68 (-2.80%)
T   19.58 (-1.26%)
F   13.14 (-0.68%)
MU   59.98 (-3.89%)
CGC   2.95 (+1.03%)
GE   82.35 (+0.48%)
DIS   109.87 (-0.76%)
AMC   6.80 (+11.84%)
PFE   43.76 (-0.68%)
PYPL   82.33 (-3.73%)
NFLX   361.48 (-1.21%)
NASDAQ:ABCL

AbCellera Biologics - ABCL Price Target & Analyst Ratings

$10.97
-0.21 (-1.88%)
(As of 02/6/2023 04:30 PM ET)
Add
Compare
Today's Range
$10.94
$11.29
50-Day Range
$9.37
$13.56
52-Week Range
$5.42
$14.97
Volume
1.13 million shs
Average Volume
1.52 million shs
Market Capitalization
$3.14 billion
P/E Ratio
13.89
Dividend Yield
N/A
Price Target
$28.67

AbCellera Biologics Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Buy
Based on 6 Analyst Ratings

Consensus Analyst Price Target

$28.67
161.32% Upside
High Prediction$40.00
Average Prediction$28.67
Low Prediction$18.00
TypeCurrent
2/6/22 to 2/6/23
1 Month Ago
1/7/22 to 1/7/23
3 Months Ago
11/8/21 to 11/8/22
1 Year Ago
2/6/21 to 2/6/22
Consensus Rating
Buy
Buy
Buy
Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
6 Buy rating(s)
6 Buy rating(s)
6 Buy rating(s)
8 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$28.67$28.67$28.40$45.86
Predicted Upside161.32% Upside172.86% Upside173.26% Upside127.56% Upside
Get AbCellera Biologics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for ABCL and its competitors with MarketBeat's FREE daily newsletter.

ABCL Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ABCL Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

AbCellera Biologics Stock vs. The Competition

TypeAbCellera BiologicsMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.64
2.46
Consensus RatingBuyBuyHold
Predicted Upside156.41% Upside3,690.57% Upside8.56% Upside
News Sentiment RatingNeutral News
Neutral News
Neutral News

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
1/6/2023SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform$20.00 ➝ $18.00+89.47%
12/15/2022The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$30.00+196.15%
11/16/2022Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$29.00+100.14%
11/1/2022Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$22.00 ➝ $21.00+79.64%
8/10/2022Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform$40.00 ➝ $34.00+181.92%
5/11/2022BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Gary Nachman
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy$40.00+571.14%
12/21/2021Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$27.00+84.93%
12/19/2021Bloom Burton
Subscribe to MarketBeat All Access for the recommendation accuracy rating
A. Borovina
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy
6/28/2021Berenberg Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy
3/30/2021Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy$59.00 ➝ $55.00+136.15%
(Data available from 2/6/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)












ABCL Price Target - Frequently Asked Questions

What is AbCellera Biologics's consensus rating and price target?

According to the issued ratings of 6 analysts in the last year, the consensus rating for AbCellera Biologics stock is Buy based on the current 6 buy ratings for ABCL. The average twelve-month price prediction for AbCellera Biologics is $28.67 with a high price target of $40.00 and a low price target of $18.00. Learn more on ABCL's analyst rating history.

Do Wall Street analysts like AbCellera Biologics more than its competitors?

Analysts like AbCellera Biologics more than other Medical companies. The consensus rating score for AbCellera Biologics is 3.00 while the average consensus rating score for medical companies is 2.64. Learn more on how ABCL compares to other companies.

Does AbCellera Biologics's stock price have much upside?

According to analysts, AbCellera Biologics's stock has a predicted upside of 172.86% based on their 12-month price targets.

What analysts cover AbCellera Biologics?

AbCellera Biologics has been rated by SVB Leerink, The Goldman Sachs Group, and Truist Financial in the past 90 days.


Stock Ratings Reports and Tools

This page (NASDAQ:ABCL) was last updated on 2/6/2023 by MarketBeat.com Staff